ES2082749T3 - Interaccion sinergica de interleucina-2 y arn de doble cadena. - Google Patents

Interaccion sinergica de interleucina-2 y arn de doble cadena.

Info

Publication number
ES2082749T3
ES2082749T3 ES88301821T ES88301821T ES2082749T3 ES 2082749 T3 ES2082749 T3 ES 2082749T3 ES 88301821 T ES88301821 T ES 88301821T ES 88301821 T ES88301821 T ES 88301821T ES 2082749 T3 ES2082749 T3 ES 2082749T3
Authority
ES
Spain
Prior art keywords
lymphokines
dsrna
human
interleukin
double chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88301821T
Other languages
English (en)
Inventor
William A Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEM Pharmaceuticals Corp
Original Assignee
HEM Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HEM Pharmaceuticals Corp filed Critical HEM Pharmaceuticals Corp
Application granted granted Critical
Publication of ES2082749T3 publication Critical patent/ES2082749T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA INVENCION SE REFIERE A UNA COMBINACION SINERGICA INESPERADA ENTRE LINFOQUINAS Y DSRNAS QUE REDUCE DRAMATICAMENTE LAS DOSIS NECESARIAS DE LINFOQUINAS, ESPECIALMENTE IL-2 Y SIMULTANEAMENTE AMPLIA SU INTERVALO TERAPEUTICO EN EL TRATAMIENTO DE VARIOS TIPOS DE CANCERES, ENFERMEDADES VIRICAS U OTROS ESTADOS CORPORALES CARACTERIZADOS POR ESTADOS INMUNES DISRREGULADOS (POR EJEMPLO ENFERMEDADES AUTOINMUNES). COMBINACIONES ESPECIFICAS DE DSRNA MAS IL-2 AUMENTAN SIGNIFICATIVAMENTE LA SUPERVIVENCIA EN ANIMALES CON MELANOMA HUMANO, EN PARTE A CAUSA DEL AUMENTO PRODUCIDO POR EL DSRNA DE CELULAS MUERTAS ACTIVADAS POR LINFOQUINA (LAK) QUE SE FORMAN EN PRIMER LUGAR COMO RESPUESTA A LA EXPOSICION A IL-2. LA INVENCION TIENEN AMPLIA APLICABILIDAD EN EL CONTROL EFICAZ NO-TOXIDO DEL CANCER Y DE VARIAS INFECCIONES VIRICAS Y ENFREMEDADES DE INMUNORREGULACION HUMANAS.
ES88301821T 1987-03-03 1988-03-02 Interaccion sinergica de interleucina-2 y arn de doble cadena. Expired - Lifetime ES2082749T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2136887A 1987-03-03 1987-03-03

Publications (1)

Publication Number Publication Date
ES2082749T3 true ES2082749T3 (es) 1996-04-01

Family

ID=21803798

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88301821T Expired - Lifetime ES2082749T3 (es) 1987-03-03 1988-03-02 Interaccion sinergica de interleucina-2 y arn de doble cadena.

Country Status (19)

Country Link
EP (1) EP0281380B1 (es)
JP (1) JPH0713024B2 (es)
KR (1) KR960008009B1 (es)
CN (1) CN1054509C (es)
AT (1) ATE130760T1 (es)
AU (2) AU1256588A (es)
CA (1) CA1336810C (es)
DE (1) DE3854726T2 (es)
DK (1) DK113188A (es)
ES (1) ES2082749T3 (es)
FI (1) FI880961A (es)
IE (1) IE75895B1 (es)
IL (1) IL85603A (es)
NO (1) NO880946L (es)
NZ (1) NZ223720A (es)
PH (1) PH24467A (es)
PT (1) PT86879B (es)
RU (1) RU1836103C (es)
ZA (1) ZA881512B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA881639B (en) * 1987-03-23 1989-02-22 Hem Res Inc Treatment of human viral infection by dsrna combined with viral inhibitors
EP0405315B1 (en) * 1989-06-30 1995-08-23 American Cyanamid Company Use of a phagocyte-activating agent : LPS or IL-2 for the manufacture of a medicament for treating staphylococcus aureus infection in cows
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
AR013269A1 (es) * 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR20010042069A (ko) 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1229134A3 (en) 2001-01-31 2004-01-28 Nucleonics, Inc Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
EP2116602A1 (en) 2008-05-07 2009-11-11 Institut Gustave Roussy Combination products for treating cancer
EA201290876A1 (ru) 2010-03-05 2013-03-29 Президент Энд Феллоуз Оф Гарвард Колледж Композиции индуцированных дендритных клеток и их использование
WO2016019472A1 (en) 2014-08-08 2016-02-11 Quest Pharmatech Inc. Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
PT86879B (pt) 1992-05-29
FI880961A0 (fi) 1988-03-02
AU1618992A (en) 1992-08-06
PT86879A (pt) 1988-04-01
DE3854726D1 (de) 1996-01-11
ATE130760T1 (de) 1995-12-15
ZA881512B (en) 1988-11-30
EP0281380A3 (en) 1989-09-27
JPS63295514A (ja) 1988-12-01
FI880961A (fi) 1988-09-04
JPH0713024B2 (ja) 1995-02-15
IL85603A0 (en) 1988-08-31
DK113188A (da) 1988-09-04
EP0281380A2 (en) 1988-09-07
IE75895B1 (en) 1997-09-24
IL85603A (en) 1993-05-13
DK113188D0 (da) 1988-03-02
EP0281380B1 (en) 1995-11-29
DE3854726T2 (de) 1996-07-25
CA1336810C (en) 1995-08-29
IE880588L (en) 1988-09-03
NZ223720A (en) 1991-07-26
KR960008009B1 (ko) 1996-06-19
CN1054509C (zh) 2000-07-19
RU1836103C (ru) 1993-08-23
NO880946L (no) 1988-09-05
AU1256588A (en) 1988-09-01
PH24467A (en) 1990-07-18
KR880010776A (ko) 1988-10-24
NO880946D0 (no) 1988-03-03
CN1032296A (zh) 1989-04-12

Similar Documents

Publication Publication Date Title
ES2082749T3 (es) Interaccion sinergica de interleucina-2 y arn de doble cadena.
OA08724A (fr) Treatment of human viral infections by dsRNA combined with viral inhibitors.
NZ226005A (en) Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof
ATE73347T1 (de) Antivirales immunotherapeutisches mittel und dessen herstellung.
UA29429C2 (uk) Фармацевтична композиція для лікування вірусних інфекцій, спосіб отримання композиції, спосіб лікування або профілактики віл-інфекції у людини
ES2099059T3 (es) Una composicion para promover el secuestro y extraccion del cuerpo de un animal de macromoleculas.
AU2003287259A1 (en) The use of endoperoxides for the treatment of infections caused by flaviviridae, including hepatitis c, bovine viral diarrhea and classical swine fever virus
ES2094702B1 (es) Composiciones farmaceuticas para la prevencion y el tratamiento de enfermedades cancerosas y procedimiento para su preparacion.
HUT65404A (en) Protection from shock subsequent to injury by double-stranded rnas
DE69106877D1 (de) Aus blaualgen hergestellte biologisch aktive verbindungen.
DE3462891D1 (en) New pyrimidine derivatives endowed with antiviral activity
ES2103811T3 (es) Terapia antiviral.
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.
MX9400210A (es) Tratamiento de infecciones virales.
ES2007094A6 (es) Procedimiento para la preparacion de 3 -c- ciano-2,3 -didesoxinucleosido.
CA2060490A1 (en) Protection from shock subsequent to injury by double-stranded rnas
CO4750838A1 (es) Metodo para el tratamiento de reacciones inflamatorias adversas y la composicion antiinflamatoria administrada

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 281380

Country of ref document: ES